Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2021 | 2017
Number of items: 2.

2021

Harbeck, Nadia ORCID: 0000-0002-9744-7372, von Schumann, Raquel, Kates, Ronald Ernest, Braun, Michael, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye ORCID: 0000-0002-5474-051X, Forstbauer, Helmut, Tio, Joke, Grischke, Eva-Maria, Biehl, Claudia, Liedtke, Cornelia, De Haas, Sanne Lysbet, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Gluz, Oleg (2021). Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers, 13 (19). BASEL: MDPI. ISSN 2072-6694

2017

Harbeck, Nadia, Gluz, Oleg, Christgen, Matthias, Kates, Ronald Ernest, Braun, Michael, Kueemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Kraemer, Stefan, Kleine-Tebbe, Anke, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, von Schumann, Raquel, Liedtke, Cornelia, Grischke, Eva-Maria, Schumacher, Johannes, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Nitz, Ulrike Anneliese (2017). De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J. Clin. Oncol., 35 (26). S. 3046 - 3057. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

This list was generated on Fri Mar 29 10:18:04 2024 CET.